1.61
price down icon10.06%   -0.18
after-market アフターアワーズ: 1.66 0.05 +3.11%
loading
前日終値:
$1.79
開ける:
$1.7
24時間の取引高:
1.37M
Relative Volume:
1.20
時価総額:
$211.17M
収益:
-
当期純損益:
$-217.44M
株価収益率:
-0.7419
EPS:
-2.17
ネットキャッシュフロー:
$-205.20M
1週間 パフォーマンス:
-19.50%
1か月 パフォーマンス:
-27.96%
6か月 パフォーマンス:
-52.79%
1年 パフォーマンス:
-72.24%
1日の値動き範囲:
Value
$1.5846
$1.71
1週間の範囲:
Value
$1.5846
$2.11
52週間の値動き範囲:
Value
$1.5846
$8.27

Prime Medicine Inc Stock (PRME) Company Profile

Name
名前
Prime Medicine Inc
Name
セクター
Healthcare (1174)
Name
電話
617-465-0013
Name
住所
60 FIRST ST., CAMBRIDGE
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
PRME's Discussions on Twitter

PRME を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
PRME
Prime Medicine Inc
1.61 211.17M 0 -217.44M -205.20M -2.17
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Prime Medicine Inc Stock (PRME) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-10 開始されました JMP Securities Mkt Outperform
2024-05-20 開始されました H.C. Wainwright Buy
2024-05-16 アップグレード Citigroup Neutral → Buy
2024-04-22 開始されました Chardan Capital Markets Buy
2024-04-08 開始されました TD Cowen Buy
2024-04-03 開始されました Wedbush Outperform
2024-01-16 ダウングレード Stifel Buy → Hold
2023-12-08 開始されました Citigroup Neutral
2023-10-09 開始されました BMO Capital Markets Outperform
2023-07-31 開始されました Guggenheim Buy
2023-04-18 開始されました Stifel Buy
2022-11-14 開始されました Goldman Neutral
2022-11-14 開始されました JP Morgan Overweight
2022-11-14 開始されました Jefferies Buy
2022-11-14 開始されました Morgan Stanley Equal-Weight
すべてを表示

Prime Medicine Inc (PRME) 最新ニュース

pulisher
Apr 01, 2025

There is no way Prime Medicine Inc (PRME) can keep these numbers up - Sete News

Apr 01, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Acquires 20,614 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World

Mar 30, 2025
pulisher
Mar 26, 2025

Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter

Mar 26, 2025
pulisher
Mar 25, 2025

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.38 - Defense World

Mar 24, 2025
pulisher
Mar 22, 2025

Wedbush Forecasts Prime Medicine FY2029 Earnings - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Chardan Capital Forecasts Strong Price Appreciation for Prime Medicine (NYSE:PRME) Stock - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Prime Medicine (NYSE:PRME) Earns “Buy” Rating from HC Wainwright - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

Why Prime Medicine Stock Was Climbing Higher This Week - Yahoo

Mar 20, 2025
pulisher
Mar 20, 2025

Prime Medicine price target raised to $16 from $15 at Chardan - TipRanks

Mar 20, 2025
pulisher
Mar 20, 2025

Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating -March 20, 2025 at 06:45 am EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 19, 2025

Why Prime Medicine Stock Is Soaring Today - Yahoo

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine announces new α1-antitrypsin deficiency program - BioWorld MedTech

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine, Inc.: Promising Future in Gene Editing with Innovative AATD Program and Strategic Growth Potential - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

H.C. Wainwright maintains Buy on Prime Medicine stock, $10 target By Investing.com - Investing.com Canada

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine, Inc.: Innovative Prime Editing Platform Targets Unmet Medical Needs with Promising Preclinical Results - TipRanks

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine (NYSE:PRME) Given “Outperform” Rating at Wedbush - Defense World

Mar 19, 2025
pulisher
Mar 19, 2025

Prime Medicine’s Promising Advancements in Liver-Targeting AATD Program with Prime Editing Technology - TipRanks

Mar 19, 2025
pulisher
Mar 18, 2025

Prime Medicine advances AATD gene editing therapy - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine, Inc.: Innovative Prime Editing Technology and Promising Preclinical Results Drive Buy Rating - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Advances AATD Program With Prime Editing For Potential Curative Treatment - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Prime sets sights on liver, lung disease as next target for its gene editing tech - BioPharma Dive

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine unveils program for treatment of AATD - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Advances AATD Program with Promising Preclinical Results - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Launches Preclinical Program for Liver Treatments -March 18, 2025 at 07:34 am EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Revolutionary Gene Editing Breakthrough: Prime Medicine's AATD Treatment Shows 95% Protein Restoration - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Prime Medicine, Inc.: Strategic Advancements and Promising Financial Outlook Drive Buy Rating - TipRanks

Mar 18, 2025
pulisher
Mar 15, 2025

Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - Benzinga

Mar 15, 2025
pulisher
Mar 14, 2025

Chardan Capital Forecasts Prime Medicine FY2025 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Prime Medicine’s SWOT analysis: gene editing firm’s stock poised for pivotal year - Investing.com

Mar 12, 2025
pulisher
Mar 10, 2025

Prime Medicine Inc (PRME)’s Market Momentum: Closing Strong at 2.40, Up 4.35 - The Dwinnex

Mar 10, 2025
pulisher
Mar 10, 2025

Is Prime Medicine Inc (NASDAQ: PRME) A Great Stock To Invest In? - Stocks Register

Mar 10, 2025
pulisher
Mar 10, 2025

Oppenheimer & Co. Inc. Decreases Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

HC Wainwright Expects Increased Earnings for Prime Medicine - Defense World

Mar 07, 2025
pulisher
Mar 04, 2025

Citizens JMP maintains $10 target on Prime Medicine stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Prime Medicine (NYSE:PRME) Given “Buy” Rating at Chardan Capital - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Prime Medicine’s Advancements and Financial Strength Support Buy Rating Amid Promising Developments in Gene Editing and Rare Diseases - TipRanks

Mar 04, 2025
pulisher
Mar 03, 2025

Prime Medicine, Inc.: Promising Gene Editing Developments and Strong Financial Position Justify Buy Rating - TipRanks

Mar 03, 2025
pulisher
Mar 03, 2025

Prime Medicine’s (PRME) “Outperform” Rating Reiterated at Wedbush - Defense World

Mar 03, 2025
pulisher
Mar 01, 2025

ARK Investment Management LLC Reduces Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Prime Medicine Reports 2024 Financial Results and Progress - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Prime Medicine, Inc. SEC 10-K Report - TradingView

Feb 28, 2025
pulisher
Feb 28, 2025

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

Can Prime Medicine's $204M Cash Boost Fuel Its Gene Editing Breakthrough? Clinical Data Coming in 2025 - StockTitan

Feb 28, 2025
pulisher
Feb 28, 2025

Prime Medicine (NYSE:PRME) vs. Bio-Techne (NASDAQ:TECH) Critical Analysis - Defense World

Feb 28, 2025
pulisher
Feb 27, 2025

News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News

Feb 27, 2025

Prime Medicine Inc (PRME) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
大文字化:     |  ボリューム (24 時間):